Vitiligo - I-Vitiligo
☆ AI Dermatology — Free Service
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
I-Non-segmental vitiligo (i‑vitiligo engahlukanisiwe)
I-vitiligo yeminwe inzima kakhulu ukuyelapha kuneminye izindawo. Noma ibukeka kabi, i-vitiligo ijwayelekile futhi ayitheleleki. Kumkhakha we-dermatology, ukwelashwa okuphumelelayo kakhulu kungaba i-phototherapy noma ukwelashwa nge-laser (excimer) izikhathi ezingu-2‑3 ngesonto, okungenani unyaka owodwa. Uma ungakwazi ukuya esibhedlela njalo ngenxa yezizathu zezimali noma ngenxa yokuba matasa, ungazama umshini we-phototherapy ovunyelwe ukusetshenziswa ekhaya.
I‑Vitiligo esandleni.
relevance score : -100.0%
ReferencesI-Vitiligo isifo esivamile sesikhumba esidala amabala amhlophe ngenxa yokulahlekelwa kwama-melanocyte. Ucwaningo lwakamuva lukhombisa ukuthi yisifo esizimele. Nakuba ngokuvamile kubhekwa njengendaba yezimonyo, kungase kuthinte ngokujulile inhlalakahle yengqondo nempilo yansuku zonke. Ngo-2011, ochwepheshe bahlukanisa uhlobo olubizwa ngokuthi segmental vitiligo ngokwehlukana nolunye.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Iziguli ezine-vitiligo ezisebenzayo zinezinketho ezimbalwa zokwelapha, njenge-systemic glucocorticoids, i-phototherapy, nama-systemic immunosuppressants. Iziguli ezizinzile ze-vitiligo zingazuza ukukhululeka nge-topical corticosteroids, ama-topical calcineurin inhibitors, i-phototherapy, nezinqubo zokufakelwa kabusha. Intuthuko yakamuva ekuqondeni izinqubo eziyisisekelo ze-vitiligo iholele ekwakhiweni kwezindlela zokwelapha ezihlosiwe. Njengamanje, ama-JAK inhibitors ayizona ezithembisa kakhulu, anikeza ukubekezelelana okuhle nemiphumela esebenzayo, naphezu kwengozi yokwenza izifo ezicashile kanye nemiphumela engemihle yesistimu evamile namanye ama-immunosuppressive agents. Ucwaningo oluqhubekayo luhlose ukukhomba ama-cytokines abalulekile abandakanyekayo ekuthuthukisweni kwe-vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Ukumisa lawa ma-cytokines kubonise isithembiso kumamodeli ezilwane nakwezinye iziguli. Ngaphezu kwalokho, uphenyo nge-miRNA-based therapeutics kanye ne-adoptive Treg cell therapy luyaqhubeka.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Alikho ikhambi elaziwayo le-vitiligo. Kulabo abanesikhumba esimhlophe, i‑sunscreen nezimonyo kuyizinto ezinconyiwe. Ezinye izindlela zokwelapha zingabandakanya ama‑steroid creams noma i‑phototherapy.
○ Ukwelashwa
#Phototherapy
#Excimer laser
#Tacrolimus ointment